Related Experiment Video
Updated: May 10, 2025
11:32
Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry
Published on: September 28, 2016
13.2K
Cardiac Channelopathies: Clinical Diagnosis and Promising Therapeutics
Ryan Dib Nehme1,2, Lilas Sinno1,2, Wael Shouman1,2
1Department of Pharmacology and Toxicology American University of Beirut Faculty of Medicine Beirut Lebanon.
Journal of the American Heart Association
|April 26, 2025
Summary
Cardiac channelopathies are inherited heart diseases affecting electrical behavior without structural issues. Research explores their genetic basis, diagnosis, and management to prevent sudden cardiac death.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Cardiac channelopathies are inherited genetic disorders of cardiomyocyte electrical activity.
- These conditions, including Long QT syndrome and Brugada syndrome, lack structural heart disease but risk malignant arrhythmias and sudden cardiac death.
- Their genetic and molecular underpinnings are complex and multifactorial.
Purpose of the Study:
- To review the molecular and genetic mechanisms of inherited arrhythmias.
- To discuss current diagnostic and management strategies for cardiac channelopathies.
- To enhance understanding and improve sudden cardiac death prevention.
Main Methods:
- Literature review of established and emerging data on cardiac channelopathies.
- Analysis of genetic and molecular foundations of inherited arrhythmias.
- Discussion of diagnostic techniques (genetic testing, electrophysiological studies) and management strategies.
Main Results:
- Cardiac channelopathies present diverse genetic and molecular bases.
- Advances in diagnostics improve identification and management.
- The link between specific genetic mutations and sudden cardiac death is still being elucidated.
Conclusions:
- Understanding the genetic and molecular basis of cardiac channelopathies is crucial.
- Improved diagnostics and management strategies are vital for preventing sudden cardiac death.
- Further research is needed to fully comprehend the relationship between genetic mutations and arrhythmogenesis.
Related Concept Videos
01:28Mechanism of Cardiac Arrhythmias
852
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
852
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.0K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
385
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
385
01:26Heart Failure Drugs: Inotropic Agents
405
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
405
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
808
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
808
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
1.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
1.9K